A cell mass-forming member that is capable of easily forming a cell mass and superior in industrial mass productivity; a culture container equipped with the cell mass-forming member; a method for producing cultured cells using the cell mass-forming member; and cultured cells with a cell mass-forming member that are equipped with the cell mass-forming member. The cell mass-forming member has a base material, an adhesion inhibition area and a cell adhesion area are formed on the surface of the base material; a micro-concavo-convex structure area including a plurality of convex portions is formed in the cell adhesion area; and a hydrophilic coating layer is formed on both the adhesion inhibition area and the cell adhesion area. The culture container and the cultured cells with a cell mass-forming member are equipped with the cell mass-forming member. The method for producing cultured cells includes using the cell mass-forming member.

The present disclosure relates to compositions and methods for culturing a population of hepatocytes in vitro, comprising co-culturing the population of hepatocytes with at least one non-parenchymal cell population and incubating the co-culture in culture medium, wherein the co-culture is periodically incubated in culture medium that does not comprise serum (serum-free culture medium).

In accordance with the present invention, an implant in which cells are arranged in a fine pattern that is available for immediate implantation and that does not need to be removed after implantation is provided. The present invention relates to a cell-containing sheet, which comprises cells and a support comprising a bioabsorbable material, in which the support has a cell adhesion protein-containing layer on the surface thereof and the cells form a pattern on the support.

The present invention relates to a process for producing a composition comprising an aqueous medium and, disposed in the aqueous medium, a first volume of a first hydrogel, which process comprises: (i) providing a composition comprising a first hydrophobic medium and, disposed in the first hydrophobic medium, a first volume of a first hydrogel; (ii) disposing a volume of an aqueous composition comprising a hydrogel compound around the first volume of the first hydrogel; (iii) allowing the aqueous composition comprising the hydrogel compound to form a gel and thereby forming a hydrogel object, which hydrogel object comprises the first volume of the first hydrogel and a second volume of a second hydrogel, which second volume of the second hydrogel is disposed around the first volume of the first hydrogel; and (iv) transferring the hydrogel object from the first hydrophobic medium to an aqueous medium and thereby producing the composition comprising the aqueous medium and, disposed in the aqueous medium, the first volume of the first hydrogel. The invention further provides a hydrogel object, which hydrogel object comprises a first volume of a first hydrogel and a second volume of a second hydrogel, which second volume of the second hydrogel is disposed around the first volume of the first hydrogel.

The present invention relates to a micro-fluid chip for blood vessel formation. The micro-fluid chip of the present invention is constituted by first to fifth channels arranged adjacent to one another on a substrate in sequence, and two or more micro-structures or micro-posts having a gap therebetween are disposed on the interface that each channel forms together with an adjacent channel while contacting the same. Each channel performs a fluidic interaction with a different channel through the gap formed by the micro-structures, and biochemical materials can move therethrough. The micro-fluid chip, according to the present invention, provides a micro-blood vessel having a flat and continuous blood vessel interface outside a body. Furthermore, cancer angiogenesis, cancer intravasation, and cancer extravasation can be modeled using the micro-fluid chip of the present invention. In addition, the micro-fluid chip of the present invention can be used to screen candidate anti-cancer drugs.

An elongated or fiber-supported multicellular aggregation of multipotent cells, wherein multipotent cells are arranged in an oblong or longish arrangement with an aspect ratio of a prolate dimension to a perpendicular dimension of at least 2:1, or supported by a fibrous structure, and wherein the aggregate contains cells at different stages of differentiation, and the aggregate contains polar cells; methods of generating such aggregates; methods of developing the aggregates further into tissue organoids and kits for such methods.

Tissue engineered constructs and methods for fabricating the disclosed constructs are provided. Some of the disclosed tissue engineered constructs are designed to fill a void in the body due to surgical resection, for example from mastectomy or lumpectomy, wounds and the like. Some disclosed constructs comprise one or more projections designed to mimic the appearance of a structural feature when implanted into a host.

The present invention provides a method of treating a disease or disorder characterized by electro-mitochondrial desynchronization in a subject in need thereof, comprising confirming the disease or disorder is characterized by electro-mitochondrial desynchronization in the subject and administering an agent that modulates mitochondrial calcium concentration and/or increases mitochondrial calcium channel activity in a tissue of the disease or disorder in the subject. Multichambered cardiac organoids comprising cardiomyocytes and endothelial cells and at least two chambers beating in synchrony are provided. Further provided are methods of using the multichambered cardiac organoid, methods of producing a cardiac organoid. Systems for making measurements within cellular aggregates or tissues and the use of same for testing therapeutic agents is also provided.

Embodiments of the disclosure include compositions and methods for providing an effective amount of activated or unactivated single-cell or spheroid fibroblasts, exosomes from fibroblasts, lysate from fibroblasts, apoptotic bodies from fibroblasts, and/or fibroblast-related products that are comprised in and/or on a substrate, such as a synthetic polymer or biopolymer scaffolding or biologic mesh, thereby generating a material to cover at least one wound and/or at least one burn of an individual.

Polymeric substrates, optionally in sheet form, treated with a thin layer of photoresist are perforated by laser ablation. Following removal of the photoresist the polymer substrates perforated with holes are patterned in stripes by photolithography, which is followed by synthesis of a cell-adhesive organometallic/self-assembled monolayer of phosphonate (SAMP) interface in the exposed regions, providing well-aligned continuous stripes for various levels of perforation. Cells plated on each of these 2-dimensional (2D) perforated surfaces attach to the interface and spread in alignment with pattern fidelity that is as high as that measured on a non-perforated, patterned substrate. A stack of such 2D patterned polymers yields a 3-dimensional (3D) device which facilitates cell growth and viability via the perforations.